GlassScriptPhysician profile
Robert M Gajdos
NPI 1649347964
$1,249.22
in general payments reported to CMS, 2019-2025
24 companies · $189 in 2025
The $189 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $342 · 2020: $52.39 · 2021: $89.97 · 2022: $202 · 2023: $179 · 2024: $195 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $563.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $562.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $163.97 | 2019 | |
| Penumbra, INC. | $125.73 | 2025 | Indigo System |
| Pfizer INC. | $109.00 | 2019-2023 | |
| Novo Nordisk INC | $107.34 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $81.49 | 2019-2024 | Veozah |
| Abbott Laboratories | $72.96 | 2022-2024 | Freestyle Libre 3, Eterna |
| Glaxosmithkline, LLC. | $67.44 | 2023-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $60.95 | 2020-2025 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.18 | 2019 | |
| Amarin Pharma, INC. | $55.99 | 2019-2021 | |
| Nevro Corp. | $46.52 | 2022 | |
| Almatica Pharma LLC | $40.44 | 2022-2023 | Gralise, Loreev Xr |
| Jazz Pharmaceuticals INC. | $39.45 | 2021-2022 | |
| Allergan, INC. | $36.06 | 2019-2020 | |
| Abbvie INC. | $35.81 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $20.14 | 2024 | Inspire |
| Seqirus USA INC | $19.00 | 2024 | Flucelvax, Fluad |
| Acadia Pharmaceuticals INC | $18.60 | 2024 | Nuplazid |
| Exact Sciences Corporation | $17.00 | 2023 | Cologuard Collection Kit |
| Optinose US, INC. | $15.16 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.00 | 2019 | |
| Genentech USA, INC. | $14.92 | 2022 | |
| Althera Pharmaceuticals LLC | $14.25 | 2022 | |
| Amgen INC. | $12.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gajdos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.